Mineralys Therapeutics, Inc. (MLYS): Pioneering Precision Hypertension Therapies Targeting Aldosterone Dysregulation

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for hypertension and related cardiovascular diseases driven by aldosterone dysregulation. The company's lead candidate, lorundrostat, is an orally administered, selective aldosterone synthase inhibitor designed to reduce aldosterone production with minimal impact on cortisol synthesis. The company generates no current revenue and is primarily funded through equity offerings and partnership agreements. Its primary stakeholders include institutional investors and a strategic collaboration with a larger pharmaceutical partner for ex-U.S. commercialization. Mineralys operates with a streamlined structure, outsourcing manufacturing and most non-core functions to focus on clinical development and regulatory strategy.

• Near-Term (12-18 Months): The primary growth driver is the completion of the Phase 3 clinical program for lorundrostat in resistant hypertension, with a New Drug Application submission targeted for 2027. Successful approval would mark the company's transition to a commercial-stage entity, with initial U.S. launch anticipated in 2027-2028.
• Medium-Term (3-5 Years): Expansion into the larger uncontrolled hypertension market, which is roughly three times the size of resistant hypertension, represents a significant growth opportunity. Additionally, a planned cardiovascular outcomes trial could support label expansion and adoption by demonstrating hard endpoint benefits, while the chronic kidney disease program opens another substantial patient population.
• Commercial Infrastructure: The company is expected to build a specialized, focused sales force targeting ~15,000 U.S. cardiologists, nephrologists, and hypertension specialists. This lean model, combined with potential partnerships for broader primary care reach, is designed to maximize the commercial opportunity while managing costs.

Source: Company filings; analyst estimates. 2025-2027 are projections.

The company remains pre-revenue, with operating losses driven by expanding clinical trial activity. R&D spending is projected to peak in 2026 as multiple Phase 3 trials and the outcomes study run concurrently. We model a first commercial launch in late 2027, generating initial revenue. Cash and investments are expected to fund operations into late 2026, necessitating additional capital raises or partnership funding before profitability.

The global hypertension therapeutics market is substantial, estimated at ~$25-30 billion annually, with the U.S. accounting for roughly 40%. Within this, the resistant and uncontrolled hypertension segments represent a significant, growing opportunity driven by an aging population and rising obesity rates. The market is dominated by generic drugs; however, novel mechanisms addressing resistant disease command premium pricing.

Key competitors in the emerging aldosterone synthase inhibitor space include:

Beyond direct competitors, Mineralys faces indirect competition from standard-of-care agents (e.g., spironolactone, eplerenone), which are inexpensive but limited by side effects. Device-based therapies like renal denervation (e.g., Medtronic's Symplicity) also target resistant hypertension and could compete for the same patient population. The company's success will depend on demonstrating a superior benefit-risk profile and establishing clear differentiation in a crowded treatment algorithm.

We employ a risk-adjusted net present value (rNPV) model to value lorundrostat. Our base-case assumptions include a 65% probability of approval in resistant hypertension, a 45% probability in uncontrolled hypertension, peak annual U.S. sales of $1.8 billion by 2032 (achieved in year 5 post-launch), and a 45% operating margin at peak. We apply a 12% discount rate to reflect clinical and commercial risk.

Comparable Company Multiples (EV/Peak Sales):

On a relative basis, MLYS trades at a discount to the peer average EV/peak sales multiple of ~1.5x, suggesting the market has not yet fully priced in the commercial potential of lorundrostat. Our DCF-derived fair value of $42.00 per share implies approximately 39% upside from the current price of $30.22.

• Clinical and Regulatory Setback: Lorundrostat could fail to meet primary endpoints in ongoing or future trials, or the FDA could raise concerns regarding hyperkalemia or other safety signals, delaying or preventing approval. The company's entire value is concentrated in this single asset.
• Commercial Competition: AstraZeneca's baxdrostat has a first-mover advantage with established commercial infrastructure and payer relationships. If baxdrostat captures the majority of the addressable market, lorundrostat's uptake could be significantly slower than projected, reducing peak sales estimates.
• Intellectual Property and Litigation: Dependence on patent protection for lorundrostat creates vulnerability to generic challenges or competitor litigation. Any loss of key patent claims could erode the commercial opportunity substantially.
• Financing and Dilution Risk: With cash runway only into late 2026 and no revenue, the company will likely need to raise additional capital, potentially at dilutive terms. This could pressure the stock price and limit upside for existing shareholders.
• High Short Interest and Market Sentiment: Short interest of 13.06% of float indicates a substantial bearish thesis, potentially related to safety concerns or skepticism about the market opportunity. Negative clinical data or delays could trigger sharp sell-offs, and the high short base may amplify volatility in either direction.